In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will probably be enrolled in the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In https://abbv-744-drug-development91346.ziblogs.com/32051779/clinical-trial-recruitment-for-abbv-744-study-fundamentals-explained